TABLE 1.
Patient characteristics at baseline.
| KRAS WT (n = 108) | KRAS mutation (n = 76) | p‐value | |
|---|---|---|---|
| Sex | 0.035 | ||
| Female | 28 (25.93%) | 10 (13.16%) | |
| Male | 80 (74.07%) | 66 (86.84%) | |
| Age(years) | <0.001 | ||
| ≤60 | 78 (72.22%) | 32 (42.11%) | |
| >60 | 30 (27.78%) | 44 (57.89%) | |
| Smoking status | <0.001 | ||
| No | 50 (46.30%) | 14 (18.42%) | |
| Yes | 58 (53.70%) | 62 (81.58%) | |
| BMI | 0.146 | ||
| ≥18.5 | 90 (83.33%) | 69 (90.79%) | |
| <18.5 | 18 (16.67%) | 7 (9.21%) | |
| ECOG‐PS | 0.597 | ||
| 0–1 | 97 (89.81%) | 70 (92.11%) | |
| 2–3 | 11 (10.19%) | 6 (7.89%) | |
| Histological type | 0.773 | ||
| Adenocarcinomas | 102 (94.44%) | 71 (93.42%) | |
| Others | 6 (5.56%) | 5 (6.58%) | |
| Stage | 0.024 | ||
| III | 10 (9.26%) | 16 (21.05%) | |
| IV | 98 (90.74%) | 60 (78.95%) | |
| Brain metastases | 0.961 | ||
| No | 87 (80.56%) | 61 (80.26%) | |
| Yes | 21 (19.44%) | 15 (19.74%) | |
| Contralateral lung metastases | 0.019 | ||
| No | 63 (58.33%) | 57 (75.00%) | |
| Yes | 45 (41.67%) | 19 (25.00%) | |
| Pleural metastases | 0.660 | ||
| No | 72 (66.67%) | 53 (69.74%) | |
| Yes | 36 (33.33%) | 23 (30.26%) | |
| Pericardial metastases | 0.073 | ||
| No | 98 (90.74%) | 74 (97.37%) | |
| Yes | 10 (9.26%) | 2 (2.63%) | |
| Liver metastases | 0.814 | ||
| No | 91 (84.26%) | 65 (85.53%) | |
| Yes | 17 (15.74%) | 11 (14.47%) | |
| Adrenal metastases | 0.062 | ||
| No | 95 (87.96%) | 59 (77.63%) | |
| Yes | 13 (12.04%) | 17 (22.37%) | |
| Bone metastases | 0.474 | ||
| No | 64 (59.26%) | 49 (64.47%) | |
| Yes | 44 (40.74%) | 27 (35.53%) | |
| Number of metastatic sites | 0.536 | ||
| <2 | 49 (45.37%) | 38 (50.00%) | |
| ≥2 | 59 (54.63%) | 38 (50.00%) | |
| First‐line treatment | <0.001 | ||
| Taxanes ± platinum | 16 (14.81%) | 5 (6.58%) | |
| Pemetrexed ± platinum | 74 (68.52%) | 28 (36.84%) | |
| Chemotherapy + antiangiogenesis/immunotherapy | 13 (12.04%) | 21 (27.63%) | |
| Unknown | 5 (4.63%) | 22 (28.95%) |
Note: p values were calculated through the chi‐square test or Fisher's exact test. p values < 0.05 were highlighted in bold.
Abbreviations: BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group Performance Status.